Drug Trial Radar · NCT06791434
Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Aug 30, 2024
Primary completion
Aug 26, 2025
Study completion Aug 26, 2025
Sponsor
- Lead sponsor
- Dr. Vishwanath Karad MIT World Peace UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed clinical study aims to evaluate the effectiveness and safety of adding Dry Needling (DN) to Conventional Treatment (CT) for patients with Myofascial Low Back Pain (MLBP). MLBP is a widespread musculoskeletal condition that causes localized pain, muscle tenderness, and functional limitations, significantly affecting the quality of life and productivity of those affected. Conventional Treatment for MLBP typically combines pharmacotherapy (e.g., NSAIDs, muscle relaxants) and physiotherapy. Dry Needling, an emerging treatment that targets myofascial trigger points with fine needles, has demonstrated promise in relieving pain and improving functional outcomes. However, no study has yet evaluated the combined effects of CT and DN. This randomized, open-label, controlled trial will involve 140 patients (70 per group) and compare the effects of CT alone versus CT combined with DN. The primary objective is to assess the change in pain intensity, while secondary objectives include improvements in pressure pain threshold, range of motion, disability, quality of life, sleep, anxiety, and depression scores. Safety will also be assessed based on adverse events and vital sign changes. The study will span 24 weeks, with 11 scheduled visits for each participant. Data analysis will be conducted to determine the added benefit of DN as an adjunctive therapy to CT, with the ultimate goal of improving treatment strategies and patient outcomes for MLBP.
Conditions
- Low Back Pain
Interventions
Fixed Dose Combination "Etoshine MR" tabletsDrug
Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
Dry needlingProcedure
Thin needle insertion
PhysiotherapyOther
Exercises
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Pain Intensity using Numeric Pain Rating Scale (NPRS)Time frame: Screening, Day 0, 3, 7, 10, 14, 28, 56, 84, 168
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sigma Spine and Pain Clinic
Pune, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.